Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

November 7, 2022

Highly differentiated programs stemming from gamma delta 1 tissue tropism and unique mechanism of action, combined with proprietary molecular engineering and armoring

ADI-925, a novel engineered chimeric adaptor (CAd) gamma delta T cell product candidate, is engineered to provide broad antitumor activity in multiple heme and solid malignancies; IND submission expected second half of 2023

Four differentiated chimeric antigen receptor (CAR) and CAd programs targeting several hematologic and solid malignancies featured at SITC

Company to unveil new details from pipeline during R&D webcast event Thursday, November 10, 2022 at 9:00 a.m. ET

REDWOOD CITY, Calif., & BOSTON--(BUSINESS WIRE)--Nov. 7, 2022-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that positive preclinical data from four new pipeline programs will be featured at poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on November 10-11, 2022.

"The emerging pipeline to be presented at SITC represents Adicet’s concerted efforts to design and deliver best-in-class gamma delta T cell therapies for cancer, today announced that positive preclinical data from four new pipeline programs will be featured at poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on November 10-11, 2022.

"The emerging pipeline to be presented at SITC represents Adicet’s concerted efforts to design and deliver best-in-class gamma delta T cell therapies," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "The new programs represent an exciting step in our evolution as a company, and we look forward to initiating additional preclinical studies designed to support the submission of investigational new drug applications to advance our first-in-class allogeneic CAR and CAd gamma delta T cell therapy product candidates for a variety of cancer indications, including solid tumors."

"The new pipeline programs have been carefully selected by integrating aspects of gamma delta 1 tissue homing, differentiated mechanisms of action, targeting enhancement and engineered armoring. Our innovative CAd and de novo CAR programs have illustrated increased proliferative potential, cytotoxicity, tumor homing, and inhibition of tumor growth in preclinical models," commented Blake T. Aftab, Ph.D., Chief Scientific Officer at Adicet Bio. "We are motivated by these encouraging results and look forward to advancing therapeutic options for patients with hematologic and solid tumor malignancies."

Adicet R&D Webcast Event Information

Adicet is hosting an R&D webcast event on Thursday, November 10, 2022, at 9:00 a.m. ET to provide additional preclinical data from its newly disclosed pipeline and upcoming milestones. Marco Davila, M.D., Ph.D., from the Roswell Park Comprehensive Cancer Center will participate in the event. The live webcast can be accessed under "Presentations & Events" in the investors section of the Company's website at www.adicetbio.com or by dialing 1-888-660-6513 (toll-free) or 1-929-203-0876 (toll) and referencing the conference ID 9936249. The archived webcast will be available on the Company's website beginning approximately two hours after the event.

Details for SITC Poster Presentations:

Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of γδ T Cell Immunotherapy
Poster/Abstract Number: 198
Presenting Author: Marissa Herrman, Ph.D.
Date/Time: November 11, 2022 from 9:00 a.m. – 9:00 p.m. ET

Title: Preclinical Discovery and Characterization of Allogeneic anti-PSMA γδ CAR T Therapy for Prostate Cancer
Poster/Abstract Number: 203
Presenting Author: Nitya Ramadoss, Ph.D.
Date/Time: November 10, 2022 from 9:00 a.m. – 9:00 p.m. ET

Title: Allogeneic “off-the-shelf” γδ T cells modified with CD27- containing CAR for targeting CD70+ cancers
Poster/Abstract Number: 246
Presenting Author: Kevin Nishimoto, Ph.D.
Date/Time: November 10, 2022 from 9:00 a.m. – 9:00 p.m. ET

Title: Preclinical Discovery and Evaluation of Allogeneic “off-the-shelf” γδ CAR T Cells Targeting B7-H6+ Tumors
Poster/Abstract Number: 247
Presenting Author: Kevin Nishimoto, Ph.D.
Date/Time: November 10, 2022 from 9:00 a.m. – 9:00 p.m. ET

Abstracts are available in a Journal for Immunotherapy of Cancer (JITC) supplement on www.sitcancer.org

About Adicet Bio, Inc.
https://www.adicetbio.com/

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and adaptors (CAd), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please
Forward-Looking Statements

This press release contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. These forward-looking statements include, but are not limited to, express or implied statements regarding the potential safety, durability, tolerability and therapeutic effects of Adicet’s preclinical programs; including the expected timing of data releases and anticipated results from ongoing and additional studies; planned investigational new drug applications for Adicet’s preclinical programs; and Adicet's progress as a company, including its R&D activities and future plans.

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on Adicet’s business and financial results, including with respect to disruptions to Adicet’s business operations and ability to raise additional capital; Adicet’s ability to execute on its strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results from preclinical studies may not necessarily be predictive of the results of any future clinical studies; any future preclinical or clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Adicet's most recent Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005164/en/